What is Tofacitinib?
Tofacitinib is a targeted synthetic disease-modifying antirheumatic drug (DMARD) that plays a significant role in managing various autoimmune and inflammatory conditions. It belongs to a class of medications known as Janus kinase (JAK) inhibitors. Unlike traditional DMARDs that broadly suppress the immune system, Tofacitinib works by selectively interfering with specific signaling pathways involved in inflammation. This targeted approach aims to reduce inflammation and alleviate symptoms associated with conditions where the immune system mistakenly attacks the body's own tissues. The most common brand name for Tofacitinib is Xeljanz. It is available in different formulations, including immediate-release and extended-release tablets, as well as an oral solution.
Mechanism of Action
Tofacitinib's therapeutic effect stems from its ability to inhibit Janus kinases (JAKs). JAKs are intracellular enzymes that are crucial for signal transduction pathways initiated by cytokines and growth factors. These cytokines are key mediators of inflammation and immune responses. When a cytokine binds to its receptor on the cell surface, it activates JAKs. The activated JAKs then phosphorylate downstream signaling molecules, most notably Signal Transducers and Activators of Transcription (STATs). Phosphorylated STATs translocate to the cell nucleus, where they regulate the transcription of genes involved in immune cell proliferation, differentiation, survival, and function. Tofacitinib primarily inhibits JAK1 and JAK3, and to a lesser extent JAK2. By blocking these enzymes, Tofacitinib interrupts the JAK-STAT signaling pathway, thereby reducing the production of pro-inflammatory cytokines and modulating the immune response. This ultimately leads to a decrease in inflammation and the associated symptoms in autoimmune diseases.
Receptor Interactions
Tofacitinib's action is closely tied to its interaction with specific JAK isoforms, which are often associated with particular cytokine receptors. For instance, JAK1 and JAK3 are commonly found in association with receptors for various interleukins (ILs) and interferons (IFNs), which are critical for lymphocyte function and immune cell signaling. By inhibiting JAK1 and JAK3, Tofacitinib can dampen the signaling cascades triggered by these pro-inflammatory cytokines, impacting T-cell activation and proliferation, which are central to many autoimmune diseases. The selective inhibition profile of Tofacitinib (preferential inhibition of JAK1 and JAK3 over JAK2) is thought to contribute to its efficacy while potentially differentiating its safety profile from other JAK inhibitors that may have broader JAK isoform inhibition.
Clinical Uses & Indications
Tofacitinib has received FDA approval for the treatment of several moderate to severely active autoimmune conditions. Its efficacy in reducing inflammation and improving clinical outcomes has made it a valuable therapeutic option for patients who have not responded adequately to conventional treatments.
FDA-Approved Uses
- Rheumatoid Arthritis (RA): Tofacitinib is indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It can be used as monotherapy or in combination with non-biologic DMARDs.
- Psoriatic Arthritis (PsA): It is also approved for adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs.
- Ulcerative Colitis (UC): Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, an intolerance, or a medical contraindication to allopathic therapy.
- Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): Tofacitinib is approved for the treatment of active polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older, who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.
The use of Tofacitinib in these indications aims to reduce joint pain and swelling, improve physical function, and slow down disease progression, thereby enhancing the quality of life for patients.
Dosage & Administration
The dosage and administration of Tofacitinib are tailored to the specific condition being treated and the patient's response. It is crucial to follow the prescribing physician's instructions carefully. Tofacitinib is available in oral formulations, including immediate-release (IR) tablets and extended-release (XR) tablets, as well as an oral solution.
Common Dosage Forms and Routes
- Immediate-Release (IR) Tablets: Typically taken orally twice daily. Dosing may vary based on the indication. For example, in rheumatoid arthritis, the usual starting dose is 5 mg twice daily.
- Extended-Release (XR) Tablets: Usually taken orally once daily. The typical dose for RA and PsA is 11 mg once daily.
- Oral Solution: Used for specific patient populations, such as children with polyarticular course juvenile idiopathic arthritis, and administered orally. The dose is calculated based on body weight.
Dosages may need to be adjusted based on factors such as renal or hepatic impairment, concomitant use of certain other medications (e.g., CYP3A4 inhibitors or inducers), and the development of adverse events. It is important to take Tofacitinib consistently as prescribed and not to change the dose or stop the medication without consulting a healthcare provider.
Side Effects & Safety
Like all medications, Tofacitinib can cause side effects, some of which can be serious. Patients should be aware of the potential risks and discuss them with their doctor. The safety profile of Tofacitinib is closely monitored by regulatory agencies due to the nature of its mechanism of action, which involves modulating the immune system.
Common Side Effects
The most frequently reported side effects associated with Tofacitinib include:
- Upper respiratory tract infections
- Headache
- Diarrhea
- Nasopharyngitis (common cold symptoms)
- Increased cholesterol levels (elevated LDL and HDL)
- Increased liver enzymes (ALT, AST)
Serious Side Effects and Contraindications
Serious side effects can occur and require immediate medical attention. These include:
- Serious Infections: Tofacitinib can lower the body's ability to fight infections, including tuberculosis (TB) and invasive fungal infections, as well as bacterial, viral, and other opportunistic infections. Patients should be screened for TB before starting treatment and monitored for signs of infection.
- Malignancy: An increased risk of certain cancers, including lymphomas and skin cancers, has been observed in patients taking JAK inhibitors.
- Thrombosis: There is an increased risk of blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis.
- Gastrointestinal Perforations: In rare cases, this can occur, particularly in patients with pre-existing diverticulitis or those taking concomitant NSAIDs or corticosteroids.
- Laboratory Abnormalities: Monitoring of complete blood counts, liver enzymes, and lipid profiles is necessary.
Contraindications: Tofacitinib is contraindicated in patients with known hypersensitivity to the drug or any of its components. It is also generally not recommended for patients with active serious infections.
Drug Interactions
Tofacitinib can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. It is essential to inform your healthcare provider about all medications, supplements, and herbal products you are currently taking.
Notable Interactions
- CYP3A4 Inhibitors: Medications that strongly inhibit the cytochrome P450 3A4 (CYP3A4) enzyme, such as ketoconazole and ritonavir, can increase Tofacitinib plasma concentrations, potentially increasing the risk of adverse events. Dosage reduction may be necessary.
- CYP2C19 Inhibitors: Medications that strongly inhibit CYP2C19, such as fluconazole, can also increase Tofacitinib exposure.
- CYP3A4 and CYP2C19 Inducers: Medications that induce these enzymes, such as rifampin, can decrease Tofacitinib plasma concentrations, potentially reducing its efficacy.
- Biologic DMARDs and Other Immunosuppressants: Concomitant use of Tofacitinib with biologic DMARDs (e.g., TNF inhibitors) or other potent immunosuppressants is generally not recommended due to an increased risk of infections.
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids: While often used concurrently for symptom management in inflammatory conditions, caution is advised due to a potential increased risk of gastrointestinal perforations.
Always consult with your physician or pharmacist regarding potential drug interactions before starting or stopping any medication while on Tofacitinib therapy.
Molecular Properties
Understanding the molecular characteristics of Tofacitinib is fundamental to comprehending its behavior and interactions within biological systems. Its chemical structure dictates its ability to bind to target enzymes and its pharmacokinetic properties.
Chemical Information
- Molecular Formula: C16H20N6O
- Molecular Weight: Approximately 312.37 g/mol
- SMILES Notation: CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12
Structure Description: Tofacitinib is a small molecule inhibitor characterized by a pyrrolo[2,3-d]pyrimidine core. This core structure is crucial for its interaction with the ATP-binding site of JAK enzymes. It features a piperidine ring substituted with a cyanoacetyl group and a methylamino group attached to the pyrrolo[2,3-d]pyrimidine moiety. The presence of the nitrile group (-C≡N) and the various nitrogen atoms within the rings contribute to its hydrogen bonding capabilities and overall molecular recognition by the target enzymes. The specific arrangement of atoms and functional groups, as precisely represented by the SMILES notation (CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12), enables its selective binding and inhibition of JAK1 and JAK3 kinases.
Frequently Asked Questions
What is Tofacitinib used for?
Tofacitinib is used to treat adults with moderate to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis who have not responded adequately to other treatments. It is also approved for active polyarticular course juvenile idiopathic arthritis in patients aged 2 years and older.
What are the common side effects of Tofacitinib?
Common side effects include upper respiratory tract infections, headache, diarrhea, nasopharyngitis, increased cholesterol levels, and elevated liver enzymes. Serious side effects can include severe infections, malignancy, thrombosis, and gastrointestinal perforations.
How does Tofacitinib work?
Tofacitinib is a Janus kinase (JAK) inhibitor. It works by blocking the activity of JAK enzymes, which are involved in signaling pathways that promote inflammation. By inhibiting these pathways, Tofacitinib reduces inflammation and helps manage autoimmune diseases.
Is Tofacitinib safe during pregnancy?
The safety of Tofacitinib during pregnancy has not been adequately established. Due to potential risks, it is generally not recommended during pregnancy unless the potential benefits outweigh the potential risks to the fetus. Women of childbearing potential should discuss contraception with their healthcare provider.
Can I take Tofacitinib with other medications?
Tofacitinib can interact with various medications, including strong CYP3A4 inhibitors and inducers, as well as other immunosuppressants. It is crucial to inform your doctor about all medications you are taking to avoid potential interactions and ensure safe use.
Analyze Tofacitinib with MolForge
Understanding the intricate molecular details, potential drug interactions, and therapeutic applications of Tofacitinib is crucial for researchers and pharmaceutical professionals. MolForge's AI-powered platform provides advanced tools to delve deeper into the properties of Tofacitinib and similar molecules. Explore its structure-activity relationships, predict potential off-target effects, and accelerate your drug discovery pipeline. Harness the power of AI to gain novel insights and drive innovation in molecular research. Visit our dashboard to start analyzing Tofacitinib and discover its full potential.